Peter MacCallum Cancer Centre (Peter Mac) is a public cancer hospital and research institute based in Melbourne, Australia. It provides comprehensive oncology services across diagnostics, medical and radiation oncology, surgery, and supportive care, alongside education and workforce training. The centre is also referred to as the Peter MacCallum Cancer Institute.
Peter Mac conducts basic, translational, and clinical research to improve cancer prevention, detection, and treatment. Its activities include biomarker and imaging research, development of novel therapies, and a broad portfolio of clinical trials. The centre collaborates with universities, healthcare providers, and industry partners to advance evidence-based cancer care and to translate laboratory findings into clinical practice.
Also known as Peter MacCallum Cancer Institute.
Phase 1b study shows pasritamig and docetaxel combo is safe and effective in prostate cancer, with high PSA response rates, supporting Phase 3 trials.
Mark Dawson becomes Head of Pharma Research and Early Development, joining from Peter MacCallum Cancer Centre, effective May 2026.
